ESC 365 - Renin-angiotensin-aldosterone system inhibitors therapy benefits and challenges in cardio-renal patients.

HFA Premium Access

Renin-angiotensin-aldosterone system inhibitors therapy benefits and challenges in cardio-renal patients.

Session: Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?

Topic: Chronic Heart Failure, Other

Speaker: Professor P. Van Der Meer (Groningen, NL)

Sponsored by Vifor Pharma

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Professor Peter Van Der Meer

University Medical Centre Groningen, Groningen (Netherlands (The))

57 presentations

4 followers

4 more presentations in this session

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Introduction

Speaker: Professor J. Cleland (Glasgow, GB)

Changing the treatment paradigm of hyperkalaemia management to enable and optimize renin-angiotensin-aldosterone system inhibitors therapy.

Speaker: Professor B. Pitt (Ann Arbor, US)

Panel discussion.

Speaker: Professor J. Butler (Dallas, US)

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors? - Summary and conclusions

Speaker: Professor J. Cleland (Glasgow, GB)

Access the full session

Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?

Speakers: Professor P. Van Der Meer, Professor J. Cleland, Professor B. Pitt, Professor J. Butler, Professor J. Cleland

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources